| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
17,892 |
13,734 |
$1.31M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,319 |
2,708 |
$153K |
| 99000 |
|
5,978 |
5,074 |
$141K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
3,063 |
2,416 |
$107K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
722 |
591 |
$103K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,254 |
933 |
$93K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
1,047 |
907 |
$88K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,112 |
1,038 |
$80K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
753 |
660 |
$63K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,514 |
2,129 |
$59K |
| 96160 |
|
2,923 |
2,653 |
$43K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,703 |
1,308 |
$42K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
799 |
681 |
$38K |
| 99255 |
|
470 |
443 |
$37K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,440 |
1,342 |
$36K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
335 |
285 |
$25K |
| 82948 |
|
5,528 |
4,189 |
$15K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
266 |
202 |
$14K |
| 99401 |
|
433 |
225 |
$11K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
556 |
527 |
$6K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
47 |
40 |
$4K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
74 |
34 |
$1K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
17 |
16 |
$1K |
| 36415 |
Collection of venous blood by venipuncture |
1,183 |
942 |
$1K |
| 99223 |
Prolong inpt eval add15 m |
25 |
17 |
$1K |
| 94760 |
|
341 |
311 |
$1K |
| 76140 |
|
16 |
15 |
$313.60 |